U.S. Biotech Industry Analysis
UpdatedAug 08, 2024
DataAggregated Company Financials
Companies560
- 7D-4.9%
- 3M4.8%
- 1Y11.5%
- YTD3.5%
Over the last 7 days, the Biotech industry has dropped 4.9%, driven by pullbacks in Moderna and Amgen of 32% and 6.9%, respectively. This takes the industry's 12 month performance to a gain of 12%. Looking forward, earnings are forecast to grow by 29% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 08 Aug 2024 | US$1.2t | US$166.2b | -US$32,645,503,888.52 | 23.4x | -35.8x | 7x |
| Sat, 06 Jul 2024 | US$1.1t | US$164.5b | -US$28,073,491,589.97 | 27.9x | -39.9x | 6.8x |
| Mon, 03 Jun 2024 | US$1.1t | US$164.6b | -US$26,677,143,877.65 | 27.4x | -42.1x | 6.8x |
| Wed, 01 May 2024 | US$1.1t | US$164.6b | -US$27,373,262,846.23 | 22.9x | -39.5x | 6.6x |
| Fri, 29 Mar 2024 | US$1.2t | US$164.4b | -US$23,753,804,933.92 | 21.4x | -49.6x | 7.2x |
| Sun, 25 Feb 2024 | US$1.2t | US$166.6b | -US$21,694,949,476.21 | 10.8x | -54.3x | 7.1x |
| Tue, 23 Jan 2024 | US$1.4t | US$204.8b | -US$22,505,965,323.00 | 18.5x | -63.5x | 7x |
| Thu, 21 Dec 2023 | US$1.4t | US$204.8b | -US$22,158,313,482.00 | 18.8x | -61.2x | 6.6x |
| Sat, 18 Nov 2023 | US$1.2t | US$204.7b | -US$22,079,363,558.00 | 18.1x | -54.7x | 5.9x |
| Mon, 16 Oct 2023 | US$1.3t | US$207.3b | -US$13,079,327,258.00 | 16.6x | -96.8x | 6.1x |
| Wed, 13 Sep 2023 | US$1.3t | US$207.5b | -US$12,640,460,182.00 | 17.5x | -101.7x | 6.2x |
| Fri, 11 Aug 2023 | US$1.3t | US$207.7b | -US$12,610,114,686.00 | 17.6x | -101.5x | 6.2x |
| Sun, 09 Jul 2023 | US$1.1t | US$186.3b | -US$16,022,507,026.00 | 12.9x | -69.1x | 5.9x |
| Tue, 06 Jun 2023 | US$1.1t | US$185.9b | -US$16,008,078,695.00 | 11.3x | -71.1x | 6.1x |
| Thu, 04 May 2023 | US$1.2t | US$197.6b | -US$7,506,497,270.00 | 14.1x | -154.8x | 5.9x |
| Sat, 01 Apr 2023 | US$1.2t | US$217.0b | -US$6,161,813,969.00 | 14.3x | -188.1x | 5.3x |
| Mon, 27 Feb 2023 | US$1.1t | US$199.7b | -US$4,454,800,065.00 | 14.2x | -251.9x | 5.6x |
| Wed, 25 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.7x | 662.2x | 5.7x |
| Fri, 23 Dec 2022 | US$1.2t | US$203.2b | US$1.6b | 14.6x | 721.2x | 5.8x |
| Sun, 20 Nov 2022 | US$1.1t | US$202.3b | US$1.2b | 14.7x | 931.7x | 5.6x |
| Tue, 18 Oct 2022 | US$1.0t | US$206.0b | US$5.4b | 15.6x | 194.3x | 5.1x |
| Thu, 15 Sep 2022 | US$1.1t | US$206.6b | US$5.7b | 15.4x | 186.4x | 5.2x |
| Sat, 13 Aug 2022 | US$1.1t | US$206.8b | US$7.3b | 15.9x | 154x | 5.4x |
| Mon, 11 Jul 2022 | US$1.1t | US$211.5b | US$10.8b | 17.4x | 102.3x | 5.2x |
| Wed, 08 Jun 2022 | US$1.0t | US$212.7b | US$11.3b | 16.6x | 90.2x | 4.8x |
| Fri, 06 May 2022 | US$1.0t | US$205.8b | US$10.3b | 17.1x | 99x | 5x |
| Sun, 03 Apr 2022 | US$1.3t | US$227.1b | US$14.5b | 18.7x | 89.7x | 5.7x |
| Tue, 01 Mar 2022 | US$1.2t | US$222.8b | US$10.9b | 19.8x | 113.4x | 5.5x |
| Thu, 27 Jan 2022 | US$1.2t | US$212.0b | US$2.4b | 22.6x | 504x | 5.7x |
| Sat, 25 Dec 2021 | US$1.4t | US$212.0b | US$2.8b | 26.1x | 519.7x | 6.8x |
| Mon, 22 Nov 2021 | US$1.5t | US$212.1b | US$3.3b | 27.1x | 442.6x | 6.9x |
| Wed, 20 Oct 2021 | US$1.5t | US$196.4b | -US$2,595,904,896.00 | 24.1x | -568.7x | 7.5x |
| Fri, 17 Sep 2021 | US$1.6t | US$196.3b | -US$2,214,200,348.00 | 25.5x | -723x | 8.2x |
| Sun, 15 Aug 2021 | US$1.6t | US$197.0b | -US$1,662,914,785.58 | 22.7x | -936x | 7.9x |
Price to Earnings Ratio
-936x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 5.5% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -5.71% | |
| Healthcare | -3.14% | |
| Biotech | -4.88% | |
| Biotech | -4.88% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$187.51 | 1.2% +US$3.9b | 24.4% | PE62.5x | |
| ALNY Alnylam Pharmaceuticals | US$260.17 | 9.6% +US$3.4b | 39.6% | PS14.2x | |
| EXAS Exact Sciences | US$55.99 | 22.6% +US$1.9b | -31.9% | PS4x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
| GRPH Graphite Bio | US$22.26 | 539.7% +US$1.1b | 861.6% | PB7.1x |
